CD86 Is an Activation Receptor for NK Cell Cytotoxicity against Tumor Cells

• DOI: 10.1371/journal.pone.0083913
• Publication Date: 2013-12-11T21:40:00Z
• Authors: Yanmeng Peng; Gaoxing Luo; Junyi Zhou; Xiaojuan Wang; Jie Hu; Yanyan Cui; Xian C. Li; Jianglin Tan; Sisi Yang; Rixing Zhan; Junjie Yang; Weifeng He; Jun Wu
• Keywords: CD86; Lymphokine-activated killer cell

CTLA4Ig has been successfully used in the clinic for suppression of T cell activation. However, patients treated with experienced reduced incidence tumors than predicted, but underlying mechanism remains unknown. In this paper, we showed that brief administration significantly tumor metastasis and prolonged survival host mice bearing B16 melanoma. Depletion NK cells prior to eliminated CTLA4Ig-mediated anti-tumor activity. enhanced cytotoxicity via up-regulation effecter molecules CD107a perforin vivo. addition, demonstrated that, upon activation, could increase expression CD86 both vitro vivo, ligation increased ability kill cells. Furthermore, a human line expressed high level was directly activated by so killing targets enhanced; be inhibited blocking CD86. Our findings uncover novel function immunity suggest on is an activating receptor closely involved response.